Cibc World Market Inc. Buys 3,879 Shares of Elevance Health, Inc. $ELV

Cibc World Market Inc. lifted its stake in Elevance Health, Inc. (NYSE:ELV) by 24.4% in the third quarter, HoldingsChannel.com reports. The fund owned 19,807 shares of the company’s stock after purchasing an additional 3,879 shares during the period. Cibc World Market Inc.’s holdings in Elevance Health were worth $6,400,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently made changes to their positions in the stock. Vermillion & White Wealth Management Group LLC grew its position in Elevance Health by 94.9% in the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 76 shares of the company’s stock worth $30,000 after purchasing an additional 37 shares during the period. BOK Financial Private Wealth Inc. purchased a new position in shares of Elevance Health in the 2nd quarter worth $32,000. Physician Wealth Advisors Inc. grew its holdings in shares of Elevance Health by 331.6% in the third quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company’s stock worth $26,000 after acquiring an additional 63 shares during the period. Activest Wealth Management increased its position in Elevance Health by 66.7% during the third quarter. Activest Wealth Management now owns 85 shares of the company’s stock valued at $27,000 after acquiring an additional 34 shares during the last quarter. Finally, Glass Jacobson Investment Advisors llc increased its position in Elevance Health by 400.0% during the second quarter. Glass Jacobson Investment Advisors llc now owns 100 shares of the company’s stock valued at $39,000 after acquiring an additional 80 shares during the last quarter. 89.24% of the stock is owned by hedge funds and other institutional investors.

Elevance Health Price Performance

Elevance Health stock opened at $346.49 on Friday. The company has a current ratio of 1.54, a quick ratio of 1.56 and a debt-to-equity ratio of 0.70. The firm has a market capitalization of $76.47 billion, a P/E ratio of 13.79, a PEG ratio of 1.93 and a beta of 0.50. The business has a 50-day moving average of $352.22 and a 200-day moving average of $332.03. Elevance Health, Inc. has a 1 year low of $273.71 and a 1 year high of $458.75.

Elevance Health (NYSE:ELV) last announced its quarterly earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.10 by $0.23. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. The company had revenue of $49.31 billion during the quarter, compared to analyst estimates of $49.52 billion. During the same quarter in the previous year, the business earned $3.84 EPS. The firm’s revenue was up 9.6% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 25.500- EPS. On average, equities analysts anticipate that Elevance Health, Inc. will post 33.96 EPS for the current year.

Elevance Health Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, March 25th. Shareholders of record on Tuesday, March 10th will be paid a $1.72 dividend. This represents a $6.88 annualized dividend and a yield of 2.0%. The ex-dividend date is Tuesday, March 10th. This is a positive change from Elevance Health’s previous quarterly dividend of $1.71. Elevance Health’s dividend payout ratio (DPR) is presently 27.23%.

Elevance Health News Summary

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Zacks raised its Q4 2027 EPS forecast to $4.75 (from $3.48), a sign that Zacks expects stronger late‑year profitability which could support the stock if sustained. Elevance Health (ELV) on MarketBeat
• Neutral Sentiment: MSN ran a stock‑perspective piece highlighting two reasons to like ELV and one caveat; the article reinforces bullish arguments around Elevance’s scale and business stability but also flags at least one risk investors should weigh. 2 reasons to like ELV (and 1 not so much)
• Negative Sentiment: Zacks issued multiple cuts to near‑term and full‑year estimates — lowering FY2026 (to $25.53 from $29.01), FY2027 (to $28.40 from $31.89) and trimming several Q1/Q2 2026–2027 quarterly forecasts — which signals weaker expected growth in the coming quarters and is a potential headwind for the stock. Zacks Research Lowers Earnings Estimates for Elevance Health

Analysts Set New Price Targets

ELV has been the subject of a number of recent research reports. UBS Group set a $400.00 price target on Elevance Health in a research note on Thursday, January 29th. Sanford C. Bernstein dropped their price objective on shares of Elevance Health from $431.00 to $409.00 and set an “outperform” rating on the stock in a report on Friday, January 30th. Guggenheim cut their target price on shares of Elevance Health from $414.00 to $396.00 and set a “buy” rating for the company in a research report on Thursday, January 29th. Wolfe Research set a $425.00 target price on shares of Elevance Health and gave the company an “outperform” rating in a report on Thursday, January 8th. Finally, Zacks Research upgraded shares of Elevance Health from a “strong sell” rating to a “hold” rating in a research note on Thursday, November 6th. Twelve research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $390.55.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.